Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al
doi:10.1016/j.bbrc.2024.149590
Although not approved for these conditions, they have also shown promise for addiction and substance use disorders, as well as Alzheimers disease and dementia
GLP-1RAs are a relatively new class of injectables that are effective at reducing HbA 1c , have a low risk of hypoglycaemia when given as monotherapy or in the absence of sulphonylureas (SU) or insulin, and have the potential for weight losskey considerations when treating a typical obese patient with T2DM [4]